Explore 3 Stock Ideas & Industry Insights Download Free Report

CeCors Inc

Healthcare US CEOS

0.0052USD
0.00(0%)

Last update at 2026-06-22T15:41:00Z

Day Range

0.00520.0052
LowHigh

52 Week Range

0.00060.02
LowHigh

Fundamentals

  • Previous Close 0.0052
  • Market Cap2.63M
  • Volume30000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.72124M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.8

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1.94M -0.34994M -1.32501M -0.49595M -0.34370M
Minority interest - - - - -
Net income 3.12M -0.35058M -1.32395M -0.49776M -0.34370M
Selling general administrative - - - - -
Selling and marketing expenses - - - - -
Gross profit - 6.26M 0.42M 0.01M -
Reconciled depreciation - - - - -
Ebit - -0.32017M -1.29750M -0.58427M -0.56822M
Ebitda -1.95817M -0.29758M -1.29530M -0.35579M -0.33166M
Depreciation and amortization - 0.02M 0.00220M 0.23M 0.24M
Non operating income net other - - - - -
Operating income -1.95817M -0.32017M -0.79750M -0.35579M -0.33166M
Other operating expenses 1.96M 6.60M 1.22M 0.38M 0.33M
Interest expense 0.03M 0.03M 0.03M 0.14M 0.01M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.00106M 0.00181M -0.23656M
Total revenue - 6.28M 0.42M 0.02M -
Total operating expenses 1.96M 6.58M 1.21M 0.37M 0.33M
Cost of revenue - 0.02M 0.00332M 0.00805M -
Total other income expense net 3.90M -0.02977M -0.52751M -0.14015M -0.01204M
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3.65M 4.12M 1.73M 0.57M 0.63M
Intangible assets - - - 0.50M 0.50M
Earning assets - - - - -
Other current assets 0.11M 0.09M 0.02M 0.02M 0.05M
Total liab 1.78M 5.14M 2.47M 1.39M 0.99M
Total stockholder equity 1.87M -1.02002M -0.74741M -0.81409M -0.36178M
Deferred long term liab - - - - -
Other current liab 0.09M 1.68M 0.37M 0.02M 0.47M
Common stock 0.31M 0.33M 0.33M 0.33M 0.50M
Capital stock - - - - -
Retained earnings 0.39M -2.73055M -2.37997M -1.05602M -0.55826M
Other liab - - - - -
Good will - 1.29M 1.29M - -
Other assets - - - 0.00000M 0.00000M
Cash 0.55M 2.27M 0.38M 0.00344M 0.07M
Cash and equivalents - - - - -
Total current liabilities 1.78M 4.33M 1.85M 0.76M 0.48M
Current deferred revenue - - - - -
Net debt -0.54585M -1.05002M 0.63M 1.32M 0.44M
Short term debt - 0.42M 0.39M 0.70M -
Short long term debt - - - - -
Short long term debt total - 1.22M 1.01M 1.32M 0.51M
Other stockholder equity 1.16M 1.37M 1.35M 0.08M -0.30378M
Property plant equipment - - - - -
Total current assets 3.15M 2.40M 0.44M 0.07M 0.13M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 2.50M - - - 0.00900M
Long term debt - - - - -
Inventory - 0.05M 0.05M 0.05M -
Accounts payable 1.69M 2.24M 1.09M 0.04M 0.00766M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00097M 0.00508M -0.05469M -0.17669M 0.00030M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.50M - - - -
Deferred long term asset charges - - - - -
Non current assets total 0.50M 1.71M 1.29M 0.50M 0.50M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - - - - -
Change to liabilities - - - - -
Total cashflows from investing activities -0.31816M -0.07866M 0.03M - 0.01M
Net borrowings - - - - -
Total cash from financing activities -0.19407M -0.15308M 0.19M 0.03M 0.15M
Change to operating activities - - - - -
Net income 1.94M -0.35058M -1.32395M -0.14071M -0.28927M
Change in cash -1.72398M 1.89M 0.37M -0.06782M 0.07M
Begin period cash flow 2.27M 0.38M 0.00344M 0.07M 0.00083M
End period cash flow 0.55M 2.27M 0.38M 0.00344M 0.07M
Total cash from operating activities 1.05M 2.13M 0.16M -0.09289M -0.09231M
Issuance of capital stock - - - - -
Depreciation - 0.02M 0.00220M - -
Other cashflows from investing activities -2.59608M - 0.16M - -
Dividends paid - - - - -
Change to inventory 0.00001M 0.00005M 0.00104M -0.00239M -
Change to account receivables - - 0.00029M -0.00090M -0.00900M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.19407M - 0.19M 0.03M 0.15M
Change to netincome - - - - -
Capital expenditures 1.05M 0.08M 0.16M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.41M 2.07M 0.54M -0.00404M -0.00846M
Stock based compensation - - - - -
Other non cash items -1.29939M 0.39M 0.94M 0.05M 0.21M
Free cash flow - 2.05M 0.16M -0.09289M -0.09231M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CEOS
CeCors Inc
- -% 0.0052 - - - - -0.0195
ISRG
Intuitive Surgical Inc
-5.27 1.30% 401.51 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme
-13.86 6.73% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA
-5.43 5.33% 96.49 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company
-2.45 1.70% 141.53 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

Profile

Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. The company was incorporated in 2002 and is based in Toronto, Canada.

CeCors Inc

17 Belfield Road, Toronto, ON, Canada, M9W1E8

Key Executives

Name Title Year Born
Mr. James J. Fiedler Chairman & CEO 1947
Mr. Robert Gardiner Pres & Director NA
Sukhinder Kalsi CFO & Director NA
Mr. Mark Perkell VP and Gen. Counsel NA
Dr. Allen Greenspoon M.D. VP & Director 1954
Mr. John Gustin Head of Global Bus. Devel. NA
Dr. Jasbir S. Kang M.D. Treasurer, Sec. & Director NA
Mr. Michael Maher Interim Chief Executive Officer NA
Mr. Amar Singh Bhatal Co-Founder, President, Secretary & Director NA
Mr. Sukhinderpaul Kalsi Co-Founder, CFO, Treasurer & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.